TY - JOUR
T1 - Expression of the multidrug transporter, P‐glycoprotein, in acute leukemia cells and correlation to clinical drug resistance
AU - Kuwazuru, Yasuo
AU - Yoshimura, Akihiko
AU - Hanada, Shuichi
AU - Utsunomiya, Atae
AU - Makino, Torahiko
AU - Ishibashi, Kazuaki
AU - Kodama, Masahiko
AU - Iwahashi, Masato
AU - Arima, Terukatsu
AU - Akiyama, Shin‐Ichi ‐I
PY - 1990/9/1
Y1 - 1990/9/1
N2 - The overexpression of a cell‐surface glycoprotein termed P‐glycoprotein (P‐gp) is frequently associated with multi‐drug resistance (MDR) in cell lines in vitro. To evaluate the implications of P‐gp expression in clinical drug resistance, the authors examined the expression of P‐gp in leukemia cells from patients with acute myelogenous leukemia (AML) and those with acute lymphoblastic leukemia (ALL) at initial presentation and relapse, using immunoblotting with a monoclonal antibody against P‐gp, C219. Nine of 17 patients with AML and four of 11 patients with ALL had P‐gp‐positive results at the initial presentation, and most P‐gp‐positive patients did not respond to chemotherapy. Four of seven patients at the relapsed stage and all three patients with preceding myelodysplastic syndrome had P‐gp‐positive results. The expression of P‐gp and clinical refractoriness to chemotherapy were highly correlated. These data indicate that the expression of P‐gp is closely related to clinical drug resistance in acute leukemia.
AB - The overexpression of a cell‐surface glycoprotein termed P‐glycoprotein (P‐gp) is frequently associated with multi‐drug resistance (MDR) in cell lines in vitro. To evaluate the implications of P‐gp expression in clinical drug resistance, the authors examined the expression of P‐gp in leukemia cells from patients with acute myelogenous leukemia (AML) and those with acute lymphoblastic leukemia (ALL) at initial presentation and relapse, using immunoblotting with a monoclonal antibody against P‐gp, C219. Nine of 17 patients with AML and four of 11 patients with ALL had P‐gp‐positive results at the initial presentation, and most P‐gp‐positive patients did not respond to chemotherapy. Four of seven patients at the relapsed stage and all three patients with preceding myelodysplastic syndrome had P‐gp‐positive results. The expression of P‐gp and clinical refractoriness to chemotherapy were highly correlated. These data indicate that the expression of P‐gp is closely related to clinical drug resistance in acute leukemia.
UR - http://www.scopus.com/inward/record.url?scp=0025088429&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025088429&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(19900901)66:5<868::AID-CNCR2820660510>3.0.CO;2-Z
DO - 10.1002/1097-0142(19900901)66:5<868::AID-CNCR2820660510>3.0.CO;2-Z
M3 - Article
C2 - 1974821
AN - SCOPUS:0025088429
SN - 0008-543X
VL - 66
SP - 868
EP - 873
JO - Cancer
JF - Cancer
IS - 5
ER -